Duncker Streett & Co. Inc. Sells 3,000 Shares of Elevance Health, Inc. (NYSE:ELV)

Duncker Streett & Co. Inc. cut its stake in Elevance Health, Inc. (NYSE:ELV - Free Report) by 40.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,492 shares of the company's stock after selling 3,000 shares during the period. Duncker Streett & Co. Inc.'s holdings in Elevance Health were worth $2,329,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. abrdn plc lifted its stake in Elevance Health by 86.8% in the fourth quarter. abrdn plc now owns 278,397 shares of the company's stock valued at $131,281,000 after buying an additional 129,364 shares during the period. Cerity Partners LLC lifted its stake in Elevance Health by 21.3% in the fourth quarter. Cerity Partners LLC now owns 52,300 shares of the company's stock valued at $24,663,000 after buying an additional 9,199 shares during the period. Wetzel Investment Advisors Inc. acquired a new position in Elevance Health in the fourth quarter valued at approximately $218,000. Chicago Capital LLC lifted its stake in Elevance Health by 244.2% in the fourth quarter. Chicago Capital LLC now owns 7,028 shares of the company's stock valued at $3,314,000 after buying an additional 4,986 shares during the period. Finally, Lecap Asset Management Ltd. acquired a new position in Elevance Health in the fourth quarter valued at approximately $2,235,000. 89.24% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Ramiro G. Peru sold 753 shares of the stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $500.00, for a total transaction of $376,500.00. Following the sale, the director now owns 9,109 shares of the company's stock, valued at approximately $4,554,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Elevance Health news, Director Ramiro G. Peru sold 753 shares of the firm's stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $500.00, for a total value of $376,500.00. Following the sale, the director now owns 9,109 shares of the company's stock, valued at approximately $4,554,500. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Felicia F. Norwood sold 14,111 shares of the firm's stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $533.74, for a total value of $7,531,605.14. Following the completion of the sale, the executive vice president now directly owns 31,460 shares in the company, valued at approximately $16,791,460.40. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

Analyst Ratings Changes

ELV has been the topic of several recent analyst reports. Wells Fargo & Company boosted their price target on Elevance Health from $557.00 to $600.00 and gave the company an "overweight" rating in a research note on Friday, April 19th. StockNews.com lowered Elevance Health from a "strong-buy" rating to a "buy" rating in a research report on Thursday, January 25th. UBS Group upped their target price on Elevance Health from $585.00 to $605.00 and gave the stock a "buy" rating in a research report on Friday, April 19th. Royal Bank of Canada upped their price target on Elevance Health from $574.00 to $575.00 and gave the stock an "outperform" rating in a report on Friday, April 19th. Finally, Barclays upped their price target on Elevance Health from $584.00 to $621.00 and gave the stock an "overweight" rating in a report on Friday, April 19th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $587.42.

Elevance Health Stock Performance

Shares of ELV stock traded up $0.77 on Thursday, hitting $525.61. 1,245,152 shares of the stock were exchanged, compared to its average volume of 1,055,526. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $122.16 billion, a PE ratio of 19.86, a P/E/G ratio of 1.17 and a beta of 0.78. Elevance Health, Inc. has a one year low of $412.00 and a one year high of $542.07. The firm's 50 day moving average is $513.28 and its two-hundred day moving average is $488.46.

Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings results on Thursday, April 18th. The company reported $10.64 earnings per share for the quarter, topping the consensus estimate of $10.54 by $0.10. The company had revenue of $42.27 billion during the quarter, compared to the consensus estimate of $42.49 billion. Elevance Health had a return on equity of 20.62% and a net margin of 3.64%. The firm's quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $9.46 EPS. Sell-side analysts expect that Elevance Health, Inc. will post 37.26 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 25th. Investors of record on Monday, June 10th will be issued a dividend of $1.63 per share. The ex-dividend date is Monday, June 10th. This represents a $6.52 dividend on an annualized basis and a yield of 1.24%. Elevance Health's dividend payout ratio (DPR) is 24.64%.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.